SpringWorks to present long-term efficacy and safety data from phase 3 DeFi trial of Ogsiveo in adults with desmoid tumours at CTOS 2024 meeting: Stamford, Connecticut Saturday, N ...

The results of the DeFi trial of nirogacestat in 142 adults with progressing desmoid tumours showed a significant 71% improvement with the drug on progression-free survival (PFS) compared to ...

An analysis of SpringWorks Therapeutics, Inc., including recent FDA approval, promising sales, and future funding for ...

Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in ...

Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with a med ...

To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to ...

Immunome, Inc. (NASDAQ:IMNM – Get Free Report) has been assigned an average recommendation of “Buy” from the six brokerages ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...